Hiroki Sumitani will assume the position of Representative Director and President effective June 26, 2026, and Osamu Matsuo is scheduled to assume the role of Director and Executive Managing Officer, Head of Pharmaceutical Business Headquarters.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4094","jir_company_name":"Nihon Kagaku Sangyo Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4094-20260428-01.pdf","jir_short_summary":"Hiroki Sumitani will assume the position of Representative Director and President effective June 26, 2026, and Osamu Matsuo is scheduled to assume the role of Director and Executive Managing Officer, Head of Pharmaceutical Business Headquarters.","jir_summary":"### Summary of Executive Personnel Changes\nNihon Kagaku Sangyo Co., Ltd. resolved at the Board of Directors meeting held on April 28, 2026, the director personnel changes effective June 26, 2026. Mr. Hiroki Sumitani will assume the position of Representative Director and President, changing from his current role as Representative Director, President, and head of Pharmaceutical Business Headquarters. Additionally, Mr. Osamu Matsuo is scheduled to become Director and Executive Managing Officer, Head of Pharmaceutical Business Headquarters. These changes will be formally approved at the Annual General Meeting of Shareholders scheduled for June 26 of the same year.\n\n### Impact on Shareholders and Corporate Strategy\nThis executive change aims to refresh the management structure and is expected to strengthen the governance of the pharmaceutical business division. The change in Representative Director and President anticipates further operational efficiency and business expansion, although the precise impact on financial performance is currently unclear. Formal approval at the shareholder meeting is required, making subsequent developments noteworthy.","jir_financial_highlights":"Appointment as Representative Director and President: Hiroki Sumitani (Effective June 26, 2026)\nNew Director Candidate: Osamu Matsuo (Effective June 26, 2026)","jir_category":"","jir_hashtags":"#NihonKagakuSangyo, #ExecutivePersonnelChanges, #JapaneseStocks","jir_key_figures":"Scheduled Appointment Date for Representative Director and President: 2026-06-26\nScheduled Appointment Date for New Director Candidate: 2026-06-26\nName of Representative Director and President: Hiroki Sumitani","jir_meta_title":"Nihon Kagaku Sangyo: Change of Representative Director and Director Personnel Changes\uff5cJune 2026","jir_meta_description":"Nihon Kagaku Sangyo Co., Ltd. announced that Hiroki Sumitani is scheduled to assume the position of Representative Director and President, and Osamu Matsuo to become Director and Executive Managing Officer effective June 26, 2026.","jir_og_title":"Nihon Kagaku Sangyo: Change of Representative Director and Director Personnel Changes\uff5cJune 2026","jir_og_description":"Nihon Kagaku Sangyo announced changes to the Representative Director and Directors in June 2026, highlighting a refresh in the management structure.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17390,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-43923","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n